Navigation Links
Pharmacyclics Reports Results for Six and Three Months Ended December 31, 2012
Date:2/14/2013

udy enrolled prior to the fourth quarter of 2013.
  • Phase III study of ibrutinib versus chlorambucil in frontline newly diagnosed elderly CLL/SLL patients, RESONATE™ -2.  This trial is a randomized, multicenter, open-label study of ibrutinib as a monotherapy versus chlorambucil in patients 65 years or older with treatment naïve CLL/SLL. The study design was granted a Special Protocol Assessment (SPA), designed to demonstrate superiority of ibrutinib with the primary endpoint of progression-free survival when compared to chlorambucil. This global study is open and Pharmacyclics plans to enroll 272 patients worldwide. The Company anticipates enrollment for this study will take approximately 18 months to complete. 
  • Phase III study of ibrutinib in combination with bendamustine and rituximab in patients with relapsed or refractory CLL/SLL, HELIOS (CLL3001). This trial is a randomized, multi-center, double blinded, placebo controlled trial of ibrutinib in combination with bendamustine and rituximab in relapsed or refractory CLL/SLL patients who received at least one line of prior systemic therapy. The primary endpoint of the study is to demonstrate a clinically significant improvement in progression-free survival when compared to bendamustine and rituximab. This global study, conducted by Janssen, is open and Janssen plans to enroll 580 patients worldwide.
  • Phase II study, RESONATE™ -17p, which is a single-arm, open-label, multi-center trial using ibrutinib as a monotherapy in patients who have deletion 17p and who did not respond to or relapsed after at least one prior treatment with chemo immunotherapy (a high unmet need population). The primary endpoint of the study will be overall response rate. This global study is open and Pharmacyclics plans to enroll 111 patients worldwide. The Company anticipates enrollment for this study will take approximately 12 months to complete.
  • Phase III study of ibrutinib ver
    '/>"/>

  • SOURCE Pharmacyclics, Inc.
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14

    Related biology technology :

    1. Pharmacyclics Reports Fiscal 2013 First Quarter Financial Results and Multiple PCI-32765 Presentations at the 54th American Society of Hematology Annual Meeting
    2. Discovery Labs Reports Third Quarter Financial Results and Progress on Lead Programs
    3. Verenium Reports Financial Results for the Third Quarter and Nine Months Ended September 30, 2011
    4. Interleukin Genetics Reports Third Quarter 2011 Financial Results
    5. Cell Therapeutics, Inc. Reports Results of Annual Meeting of Shareholders
    6. Nile Therapeutics Reports 2011 Third Quarter Financial Results
    7. Pharmasset Reports Fiscal Year End 2011 Financial Results
    8. Palatin Technologies, Inc. Reports First Quarter Fiscal Year 2012 Results; Teleconference and Webcast to be held on November 15, 2011
    9. SeraCare Reports Fiscal Year 2011 and Fourth Quarter Financial Results
    10. WaferGen Reports Third Quarter 2011 Financial Results and Announces New Commercialization Strategy
    11. Hadasit Bio-Holdings Ltd. Reports Significant External Financing for Portfolio Companies
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:4/16/2015)... ON , April 16, 2015 /CNW/ - Bioenterprise Corporation ... its newest office in Charlottetown , ... the Prince Edward Island ADAPT Council for the commercialization ... looking forward to working with PEI ADAPT.  They have ... for more than a decade," explains Dave Smardon ...
    (Date:4/16/2015)...  Scientists from Cleave Biosciences will be participating in ... the American Association for Cancer Research Annual Meeting 2015 ... April 19, 2015 from 3:15pm to 5:15pm ET. ... present new in vivo and mechanism of action study ... a critical enzyme that controls various aspects of protein ...
    (Date:4/16/2015)... and MENLO PARK, Calif. , ... (OTCQX: DMPI) (DelMar and the Company), a biopharmaceutical company ... new orphan drug indications, today announced that the ... a clinical trial site for the ongoing, multicenter Phase ... multiforme (GBM), the most common and deadly form of ...
    (Date:4/16/2015)... April 16, 2015 Modality Solutions, ... systems for highly regulated industries, is pleased to ... a monthly columnist for Cold Chain IQ - ... ). His column titled, Global Cold Chain Connections, ... for today’s life sciences, pharmaceutical and healthcare supply ...
    Breaking Biology Technology:Bioenterprise Corporation Expands into the Maritimes 2Cleave Biosciences to Participate in Special Session "New Drugs on the Horizon" at AACR Annual Meeting 2015 2Cleave Biosciences to Participate in Special Session "New Drugs on the Horizon" at AACR Annual Meeting 2015 3DelMar Pharmaceuticals Adds Fourth Clinical Trial Site in Phase I/II Multicenter Study of VAL-083 for Recurrent Malignant Glioma 2DelMar Pharmaceuticals Adds Fourth Clinical Trial Site in Phase I/II Multicenter Study of VAL-083 for Recurrent Malignant Glioma 3DelMar Pharmaceuticals Adds Fourth Clinical Trial Site in Phase I/II Multicenter Study of VAL-083 for Recurrent Malignant Glioma 4DelMar Pharmaceuticals Adds Fourth Clinical Trial Site in Phase I/II Multicenter Study of VAL-083 for Recurrent Malignant Glioma 5Modality Solutions Gary Hutchinson Named Columnist for Cold Chain IQ 2Modality Solutions Gary Hutchinson Named Columnist for Cold Chain IQ 3
    ... BioPharma Corp. (TSX, FSE: "HBP") today announced that John ... the BioFinance 2009 Investor Conference at 3:00 p.m. EDT ... Toronto. Mr. Docherty will provide an overview of ... its current product development programs, L-DOS47 and Topical Interferon ...
    ... Medical Corp (TSX: MS), a leading developer in the treatment of multiple ... present at BioFinance 2009 in Toronto., WHEN: Wednesday ... Eaton Centre Hotel (Trinity V room), ... Toronto, ON, About BioFinance ...
    ... Ltd, announced,today that it has been engaged by ... in,divesting its world class research centre, the IRBM, ... pharmaceutical,transactions experience in the healthcare and investment business ... and biological,discovery centre. IRBM has an outstanding record ...
    Cached Biology Technology:Helix BioPharma to Present at the BioFinance 2009 Conference 2BioMS Medical to present at BioFinance 2009 2Merck Engages PharmaVentures to Assist in the Divestment of its Italian Research Centre IRBM 2
    (Date:3/31/2015)... -- Elephant Talk Communications Corp. (NYSE MKT: ETAK) ("Elephant Talk" ... Network Architecture (ET Software DNA® 2.0) platforms and cyber ... million for the year ended December 31, 2014 as ... ended December 31, 2013. At the ... multi-year transition away from its legacy landline business to ...
    (Date:3/24/2015)... , Mar. 24, 2015 Research and Markets ... and Voice Biometrics - Global Strategic Business Report" report to ... Face and Voice Biometrics in US$ Thousands by the following Segments: ... for the US, Canada , Japan ... , Middle East & Africa ...
    (Date:3/23/2015)... -- In the 2014 fiscal year, irs.gov recorded over $100 ... accounts for a fraction of the estimated losses for ... $11 billion globally. The polygraph has traditionally been used ... Investor Mark Saint Juste along with former ... partnered to administer the test in a new way: ...
    Breaking Biology News(10 mins):Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 2Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 3Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 4Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 5Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 6Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 2Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 3Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 4Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 5Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 6Polygraph Test Now Used to Protect Investors From Fraud 2Polygraph Test Now Used to Protect Investors From Fraud 3
    ... May 1, 2009 Signal Hill, CA ... firm that helps organizations make sustainable transformations, has ... change communication programs required to encourage sustainable behaviors ... , The paper, entitled "A Turning Point in ...
    ... miss your daily cup of coffee and subsequently ... consumers of coffee and other caffeinated products, caffeine ... feeling less alert, less energetic and experiencing difficulty ... of Medicine and Johns Hopkins School of Medicine ...
    ... 2009) For the first time, scientists have discovered ... and dissections as well as early onset coronary artery ... led by scientists at The University of Texas Health ... Smooth Muscle Alpha-Actin (ACTA2) Cause Early Onset Coronary Artery ...
    Cached Biology News:Your brain on -- and off -- caffeine 2Single gene defect can cause stroke, other artery diseases 2Single gene defect can cause stroke, other artery diseases 3
    ... Two-Color RNA Spike-In Kit contains in vitro ... to complementary control probes on Agilents microarrays, ... serve as a positive microarray control in ... This kit is a required component of ...
    ... human adult normal Mega Western Protein Array ... The Mega Western Protein Arrays are manufactured ... documented tissue sources. A protein sample from ... along with a Protein molecular weight marker ...
    ... For applications not requiring confocal, the ... alternative to the Pathway 435. And, the ... if later applications require it. ... can elect to use the laser autofocus, ...
    fully automated system for the processing of microarrays on microscope slides...
    Biology Products: